NASDAQ · BBOT
BridgeBio Oncology Therapeutics, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for BBOT: Nov 11, 2026
BridgeBio Oncology Therapeutics, Inc. Common Stock is estimated to report earnings on 11/11/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 8 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.65. The reported EPS for the same quarter last year was $-1.03.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.65 | $-0.54 | $-0.72 | 8 |
| Dec 2026 | $-0.66 | $-0.55 | $-0.72 | 8 |
| Mar 2027 | $-0.64 | $-0.51 | $-0.73 | 5 |
| Jun 2027 | $-0.67 | $-0.50 | $-0.74 | 5 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Fintel · RTTNews- Fintel · May 11, 8:04 PM EDTCanaccord Genuity Initiates Coverage of BridgeBio Oncology Therapeutics (BBOT) with Buy RecommendationFintel reports that on May 11, 2026, Canaccord Genuity initiated coverage of BridgeBio Oncology Therapeutics (NasdaqGM:BBOT) with a Buy recommendation. Analyst Price Forecast Suggests 228.46% Upside
- RTTNews · Apr 23, 10:30 AM EDTBridgeBio Announces Positive Preclinical Data For BBO-11818 In Targeting KRAS-Mutant Tumors(RTTNews) – BridgeBio Oncology Therapeutics Inc. (BBOT), a clinical-stage biopharmaceutical company, on Wednesday presented promising preclinical data on BBO-11818, a drug developed for the treatment of KRAS-mutant cancers, at the 2026 annual meeting of the American Association f
- RTTNews · Apr 22, 9:04 AM EDTBridgeBio Reports Promising Preclinical Data For BBO-10203 In HER2 Cancer Cell Lines(RTTNews) – BridgeBio Oncology Therapeutics Inc. (BBOT), a clinical-stage biopharmaceutical company, on Tuesday presented preclinical data evaluating BBO-10203 in blocking interactions between RAS an PI3Ka in tumors at the 2026 annual meeting of the American Association of Cancer
- RTTNews · Apr 21, 2:54 AM EDTBridgeBio Oncology Gets FDA Fast Track Tag For BBO-11818 In KRAS-mutant Pancreatic Cancer(RTTNews) – BridgeBio Oncology Therapeutics, Inc. (BBOT) said the U.S. Food and Drug Administration has granted Fast Track designation to BBO-11818 for the treatment of adults with advanced KRAS-mutant pancreatic ductal adenocarcinoma.
- Fintel · Feb 11, 4:31 PM ESTStifel Initiates Coverage of BridgeBio Oncology Therapeutics (BBOT) with Buy RecommendationFintel reports that on February 11, 2026, Stifel initiated coverage of BridgeBio Oncology Therapeutics (NasdaqGM:BBOT) with a Buy recommendation. Analyst Price Forecast Suggests 127.17% Upside
- Fintel · Jan 9, 7:04 PM ESTRaymond James Initiates Coverage of BridgeBio Oncology Therapeutics (BBOT) with Outperform RecommendationFintel reports that on January 9, 2026, Raymond James initiated coverage of BridgeBio Oncology Therapeutics (NasdaqGM:BBOT) with a Outperform recommendation. Analyst Price Forecast Suggests 80.23% Upside
- Fintel · Dec 11, 7:06 PM ESTWedbush Reiterates BridgeBio Oncology Therapeutics (BBOT) Outperform RecommendationFintel reports that on December 11, 2025, Wedbush reiterated coverage of BridgeBio Oncology Therapeutics (NasdaqGM:BBOT) with a Outperform recommendation. Analyst Price Forecast Suggests 90.51% Upside
- Fintel · Dec 5, 4:53 PM ESTMorgan Stanley Initiates Coverage of BridgeBio Oncology Therapeutics (BBOT) with Overweight RecommendationFintel reports that on December 5, 2025, Morgan Stanley initiated coverage of BridgeBio Oncology Therapeutics (NasdaqGM:BBOT) with a Overweight recommendation. Analyst Price Forecast Suggests 112.13% Upside
- Fintel · Nov 13, 7:06 PM ESTOppenheimer Maintains BridgeBio Oncology Therapeutics (BBOT) Outperform RecommendationFintel reports that on November 13, 2025, Oppenheimer maintained coverage of BridgeBio Oncology Therapeutics (NasdaqGM:BBOT) with a Outperform recommendation. Analyst Price Forecast Suggests 99.39% Upside
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Financials
Loading fundamental data…
More headlines
More stories for BridgeBio Oncology Therapeutics, Inc. from TradingView. Coverage varies.
Loading related news…
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.